Beam Therapeutics IncNASDAQ:BEAM
- LAST PRICE24.4400
- TODAY'S CHANGE (%)-0.6100 (-2.4351%)
- Bid / Lots24.4200/ 3
- Ask / Lots24.4600/ 6
- Open / Previous Close24.9400 / 25.0500
- Day Range
- 52 Week Range
- Volume262,099
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BEAM |
|---|---|---|
| 09:32 ET | 9505 | 24.86 |
| 09:34 ET | 370 | 24.825 |
| 09:36 ET | 10747 | 24.785 |
| 09:38 ET | 1429 | 25.105 |
| 09:39 ET | 200 | 25.1875 |
| 09:41 ET | 795 | 25.21 |
| 09:43 ET | 780 | 25.18 |
| 09:45 ET | 400 | 25.14 |
| 09:48 ET | 4385 | 25.12 |
| 09:50 ET | 7447 | 25.1756 |
| 09:52 ET | 1350 | 25.18 |
| 09:54 ET | 600 | 25.23 |
| 09:56 ET | 300 | 25.12 |
| 09:57 ET | 1105 | 25.06 |
| 09:59 ET | 400 | 24.86 |
| 10:01 ET | 300 | 24.86 |
| 10:03 ET | 500 | 24.92 |
| 10:06 ET | 479 | 24.94 |
| 10:08 ET | 1087 | 25.006 |
| 10:10 ET | 100 | 24.995 |
| 10:12 ET | 400 | 24.94 |
| 10:14 ET | 900 | 24.85 |
| 10:17 ET | 2400 | 24.76 |
| 10:19 ET | 1400 | 24.7711 |
| 10:21 ET | 3736 | 24.75 |
| 10:24 ET | 4279 | 24.815 |
| 10:26 ET | 2579 | 24.835 |
| 10:28 ET | 1600 | 24.845 |
| 10:30 ET | 5580 | 24.79 |
| 10:32 ET | 850 | 24.83 |
| 10:33 ET | 100 | 24.83 |
| 10:35 ET | 2625 | 24.86 |
| 10:37 ET | 1350 | 24.85 |
| 10:39 ET | 1700 | 24.81 |
| 10:42 ET | 1432 | 24.82 |
| 10:44 ET | 401 | 24.8 |
| 10:46 ET | 556 | 24.82 |
| 10:48 ET | 4125 | 24.875 |
| 10:50 ET | 514 | 24.87 |
| 10:51 ET | 300 | 24.8 |
| 10:53 ET | 400 | 24.8 |
| 10:55 ET | 650 | 24.8 |
| 10:57 ET | 1569 | 24.76 |
| 11:00 ET | 800 | 24.73 |
| 11:02 ET | 400 | 24.765 |
| 11:04 ET | 5824 | 24.8 |
| 11:06 ET | 1678 | 24.76 |
| 11:08 ET | 2754 | 24.81 |
| 11:09 ET | 1299 | 24.805 |
| 11:11 ET | 800 | 24.75 |
| 11:13 ET | 2397 | 24.79 |
| 11:15 ET | 400 | 24.79 |
| 11:18 ET | 794 | 24.88 |
| 11:20 ET | 500 | 24.81 |
| 11:24 ET | 200 | 24.8 |
| 11:27 ET | 600 | 24.74 |
| 11:29 ET | 500 | 24.74 |
| 11:31 ET | 1200 | 24.72 |
| 11:33 ET | 400 | 24.73 |
| 11:36 ET | 2100 | 24.64 |
| 11:38 ET | 800 | 24.62 |
| 11:40 ET | 4125 | 24.63 |
| 11:42 ET | 3089 | 24.595 |
| 11:44 ET | 4296 | 24.62 |
| 11:45 ET | 1425 | 24.62 |
| 11:47 ET | 845 | 24.585 |
| 11:49 ET | 1733 | 24.63 |
| 11:51 ET | 1500 | 24.6 |
| 11:54 ET | 2228 | 24.585 |
| 11:56 ET | 800 | 24.57 |
| 11:58 ET | 5940 | 24.575 |
| 12:00 ET | 1300 | 24.57 |
| 12:02 ET | 400 | 24.54 |
| 12:03 ET | 1396 | 24.58 |
| 12:05 ET | 300 | 24.55 |
| 12:07 ET | 5526 | 24.54 |
| 12:09 ET | 2253 | 24.59 |
| 12:12 ET | 1400 | 24.63 |
| 12:14 ET | 1500 | 24.63 |
| 12:16 ET | 369 | 24.63 |
| 12:18 ET | 2472 | 24.68 |
| 12:20 ET | 1100 | 24.72 |
| 12:21 ET | 3083 | 24.66 |
| 12:23 ET | 1375 | 24.725 |
| 12:25 ET | 100 | 24.695 |
| 12:27 ET | 100 | 24.695 |
| 12:30 ET | 200 | 24.7 |
| 12:32 ET | 750 | 24.73 |
| 12:34 ET | 553 | 24.73 |
| 12:36 ET | 500 | 24.71 |
| 12:38 ET | 200 | 24.73 |
| 12:39 ET | 500 | 24.725 |
| 12:41 ET | 1282 | 24.61 |
| 12:43 ET | 1526 | 24.64 |
| 12:45 ET | 100 | 24.635 |
| 12:48 ET | 855 | 24.7 |
| 12:50 ET | 400 | 24.66 |
| 12:52 ET | 1728 | 24.64 |
| 12:54 ET | 612 | 24.63 |
| 12:56 ET | 1420 | 24.61 |
| 12:59 ET | 2665 | 24.58 |
| 01:01 ET | 1928 | 24.49 |
| 01:06 ET | 750 | 24.464 |
| 01:08 ET | 913 | 24.45 |
| 01:10 ET | 1300 | 24.46 |
| 01:12 ET | 2528 | 24.46 |
| 01:14 ET | 2850 | 24.455 |
| 01:15 ET | 200 | 24.49 |
| 01:17 ET | 150 | 24.46 |
| 01:19 ET | 1464 | 24.45 |
| 01:21 ET | 700 | 24.42 |
| 01:24 ET | 400 | 24.44 |
| 01:26 ET | 481 | 24.44 |
Sep 19, 2024
DJ Beam Therapeutics Price Target Maintained With a $27.00/Share by RBC Capital, from 9:30AM ET on Thursday Sep 19, 2024 by Dow Jones
9:30AM ET on Thursday Sep 19, 2024 by Dow Jones
Sep 17, 2024
DJ Beam Therapeutics Initiated at Hold by Jones Trading, from 5:01PM ET on Tuesday Sep 17, 2024 by Dow Jones
5:01PM ET on Tuesday Sep 17, 2024 by Dow Jones
Sep 11, 2024
DJ Beam Therapeutics Is Maintained at Buy by Stifel, from 7:52AM ET on Wednesday Sep 11, 2024 by Dow Jones
7:52AM ET on Wednesday Sep 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Beam Therapeutics Inc | 2.2B | -13.8x | --- |
Galapagos NV | 2.0B | 54.1x | --- |
Catalyst Pharmaceuticals Inc | 2.4B | 36.8x | --- |
Veracyte Inc | 2.5B | -45.7x | --- |
Genmab A/S | 17.4B | 19.3x | +22.71% |
Maravai LifeSciences Holdings Inc | 2.1B | -8.3x | --- |
Company Information
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Contact Information
- Headquarters
- 238 Main StreetCAMBRIDGE, MA, United States 02142
- Phone
- 857-327-8775
- Fax
- 302-655-5049
Executives
- President
- Giuseppe Ciaramella
- Chief Executive Officer, Principal Financial and Accounting Officer, Director
- John Evans
- Chief Financial Officer, Treasurer
- Terry-Ann Burrell
- Chief Medical Officer
- Amy Simon
- Chief Legal Officer and Secretary
- Christine Bellon
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
|---|---|
Revenue (TTM) | $352.6M |
Shares Outstanding | 82.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.85 |
EPS | $-1.76 |
Book Value | $12.02 |
P/E Ratio | -13.8x |
Price/Sales (TTM) | 6.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -52.31% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
